ClinicaliQ Trial Snapshot
- A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia — Recruiting • Phase II • NCT06079398.
- TransCon CNP (navepegritide) weekly injections versus placebo tested for safety and effectiveness in babies with achondroplasia.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to < 2 years at the time of randomization. Conditions: Achondroplasia Interventions: Navepegritide, Placebo for Navepegritide Lead Sponsor: Ascendis Pharma A/S Planned Enrollment: 72 participants